Deep Venous Thrombosis (DVT) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034

 Deep Venous Thrombosis (DVT) Market Outlook

Thelansis’s “Deep Venous Thrombosis (DVT) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Deep Venous Thrombosis (DVT) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Deep Venous Thrombosis (DVT) Overview

Deep Venous Thrombosis (DVT) is a pathological condition characterized by the obstruction of veins due to hindered venous reflux. It predominantly affects the lower limb venous system, originating from clot formation in a deep calf vein and extending proximally. DVT and venous thromboembolism (VTE) significantly contribute to cardiovascular disease mortality, ranking third after heart attacks and strokes. Various risk factors contribute to the development of DVT, including reduced blood flow, increased venous pressure, mechanical injury to the vein, and elevated blood viscosity. Established causes of DVT and VTE include obesity, pregnancy, advanced age (above 60), surgery, critical care admission, dehydration, and cancer. According to Virchow’s triad, the main pathophysiological mechanisms involved in DVT are damage to the vessel wall, blood flow turbulence, and hypercoagulability. Deep veins, as categorized by the Clinical-Etiology-Anatomy-Pathophysiology (CEAP) classification, include the inferior vena cava, common iliac, internal and external iliac, pelvic veins (including gonadal and broad ligament veins), common femoral, deep femoral vein, femoral, popliteal, paired crural veins of anterior and posterior tibial and peroneal, and muscular veins of gastrocnemial and soleal. The severity of DVT is classified into provoked and unprovoked cases. Provoked DVT occurs due to acquired conditions such as surgery, oral contraceptive use, trauma, immobility, obesity, and cancer. Unprovoked DVT has idiopathic or endogenous causes and carries a higher risk of recurrence if anticoagulation treatment is discontinued. DVT can be further categorized as proximal (above the knee, affecting the femoral or iliofemoral veins) or distal (below the knee). The primary complications associated with DVT are pulmonary embolism (including paradoxical emboli in the presence of an atrial septal defect), post-thrombotic syndrome, and bleeding from anticoagulant medications.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2024–2034)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: Deep Venous Thrombosis (DVT) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034